Why Compare Side Effects Before Choosing Your Treatment?
Understanding Wegovy vs Mounjaro Side Effects Profiles
The side effects of Wegovy differ from Mounjaro due to their distinct mechanisms of action, making comparison essential for informed treatment selection. Wegovy contains semaglutide, a selective GLP-1 receptor agonist, whilst Mounjaro utilises tirzepatide, which targets both GIP and GLP-1 receptors simultaneously. This dual-action approach of Mounjaro may influence gastrointestinal tolerance differently compared to Wegovy's single-pathway mechanism. Both treatments share common side effects including nausea, vomiting, and diarrhoea, but the intensity and duration can vary between individuals.
Clinical data suggests that the side effects of Wegovy typically emerge during dose escalation phases, with most patients experiencing peak symptoms during the first 8-12 weeks of treatment. Mounjaro's dual mechanism may produce different timing patterns for side effect onset and resolution. The graduated dosing schedules—Wegovy's 5-dose progression from 0.25mg to 2.4mg versus Mounjaro's 6-dose escalation from 2.5mg to 15mg—are specifically designed to minimise gastrointestinal side effects for each medication. Understanding these differences helps prescribers tailor treatment selection to individual patient tolerance profiles.
Wegovy vs Mounjaro Pricing and Treatment Value
EverydayMeds offers comprehensive pricing for both treatments, with Wegovy single pens starting at £79.99 for the 0.25mg starter dose (new customers apply code FIRST40 at checkout). Our Wegovy dosing progression includes £94.99 for 0.5mg, £99.99 for 1mg, £139.99 for 1.7mg, and £209.99 for the 2.4mg maintenance dose. Returning customers benefit from code DOSE25 applied at checkout across all strengths. Mounjaro pricing follows a different structure reflecting its unique dosing schedule and dual-mechanism formulation.
Our bundling options provide treatment continuity for both medications, with the Intro Duo (0.25mg & 0.5mg Wegovy) available for £169.99, and the Progress Trio (0.5mg, 1mg & 1.7mg) at £369.99. The Ultimate Stability Trio delivers three months of 2.4mg maintenance supply for £649.99, ensuring uninterrupted treatment. These bundles offer convenience through fewer orders and Reliable Supply continuity. Both Wegovy and Mounjaro require prescription-only medicine protocols with full clinical assessment through our GPhC-registered pharmacy (#9012878).
Clinical Evidence Comparing Wegovy vs Mounjaro Side Effects
The STEP trials for Wegovy and SURMOUNT studies for Mounjaro provide valuable insights into comparative side effect profiles, though direct head-to-head comparisons require careful interpretation due to different trial designs. In the STEP 1 trial (Wilding et al., NEJM, 2021), the most common side effects of Wegovy included nausea (44% vs 11% placebo), vomiting (24% vs 5%), and diarrhoea (30% vs 15%). These gastrointestinal effects were generally transient and decreased over time with continued treatment.
Mounjaro's SURMOUNT trials demonstrated similar gastrointestinal side effect patterns but with potentially different severity profiles due to its dual GIP/GLP-1 mechanism. The comparative tolerability between these treatments may vary significantly between individuals, influenced by factors including baseline gastrointestinal sensitivity, dose escalation adherence, and concurrent medications. Both treatments showed that side effects were most pronounced during initial dose escalation phases and generally improved with continued therapy.
How Wegovy Works: GLP-1 Mechanism and Side Effects
Wegovy's active ingredient semaglutide functions as a GLP-1 receptor agonist, mimicking the natural incretin hormone that regulates appetite and gastric emptying. This mechanism directly influences the brain's appetite centres whilst slowing gastric motility, which contributes to both the therapeutic effects and characteristic side effect profile. The delayed gastric emptying that enhances satiety can also cause nausea and vomiting, particularly during initial treatment phases. Understanding this connection helps patients recognise that many side effects of Wegovy stem from the same mechanisms producing therapeutic benefits. The once-weekly FlexTouch pen delivery system maintains steady semaglutide levels, designed to minimise peak-related side effects whilst maximising therapeutic efficacy throughout the dosing interval.
EverydayMeds Ordering Process for Both Treatments
Our streamlined ordering process begins with a comprehensive 3-minute online clinical assessment covering medical history, current medications, and treatment goals for both Wegovy and Mounjaro. Qualified prescribers review applications within standard 3 working days (express 24-hour review available), evaluating suitability for either treatment based on individual patient factors including side effect risk assessment. Once approved, both medications ship via next-day delivery using temperature-controlled cold-chain logistics to maintain pharmaceutical integrity. Our GPhC-registered pharmacy ensures full regulatory compliance throughout the supply chain. Patient support continues post-delivery with clinical guidance on dose escalation, side effect management, and treatment optimisation for whichever medication your prescriber recommends.
Storage and Practical Considerations: Wegovy vs Mounjaro
Wegovy offers superior storage flexibility compared to Mounjaro, remaining stable for 6 weeks at room temperature (below 30°C) once removed from refrigeration, versus Mounjaro's 21-day room temperature limit. This advantage proves particularly valuable for travel or workplace storage where refrigeration access is limited. Both medications require initial storage at 2-8°C and utilise pen injection systems, though Wegovy's FlexTouch technology offers distinct ergonomic advantages. The dose escalation schedule differences—Wegovy's 4-week intervals versus Mounjaro's varied progression—impact treatment planning and side effect monitoring approaches. Understanding these practical aspects helps patients prepare for long-term treatment success whilst managing potential side effects of Wegovy or Mounjaro effectively.
Choosing Between Wegovy and Mounjaro Based on Side Effect Tolerance
Individual side effect tolerance often determines optimal treatment selection between Wegovy's single GLP-1 pathway and Mounjaro's dual GIP/GLP-1 mechanism. Patients with previous GLP-1 experience may have established tolerance patterns that inform prescriber recommendations. The different molecular structures and receptor binding profiles can result in varied gastrointestinal responses, making personalised selection crucial. Some patients may experience better tolerance with one mechanism over the other, despite similar overall side effect categories.
EverydayMeds' unique position supplying both treatments allows prescribers flexibility in treatment switching if initial side effect profiles prove challenging. This availability removes common barriers where pharmacies stock only one option, potentially limiting optimal patient care. Both treatments require identical lifestyle modifications including reduced-calorie diet and increased physical activity, ensuring that treatment switching doesn't compromise the comprehensive weight management approach. Your prescriber can evaluate your specific risk factors and preferences to recommend the most appropriate option.
Complete Treatment Support and Expert Guidance
EverydayMeds provides comprehensive support for managing side effects of Wegovy or Mounjaro through our clinical team's expertise in weight management treatments. New customers access both treatments using code FIRST40 at checkout, whilst returning customers apply code DOSE25 for continued savings across either treatment option. Our next-day delivery ensures prompt treatment initiation once prescribed, with temperature-controlled logistics maintaining pharmaceutical integrity. Both medications represent prescription-only medicines requiring full clinical oversight throughout treatment. Visit https://everydaymeds.co.uk/collections/weight-loss to begin your clinical assessment and discover which treatment offers optimal side effect management for your individual needs.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
